Complementary and Alternative Medicine Provider Use and Expenditures by Cancer Treatment Phase
More than 26% of cancer patients see CAM providers, primarily for musculoskeletal problems; use does not vary by treatment phase, and associated expenditures are low.
Using a prioritization algorithm in an oncology pharmacy system at the Johns Hopkins University, patient wait times for chemotherapy administration were significantly decreased.
Second-line and Third-line Chemotherapy for Lung Cancer: Use and Cost
Using health insurance claims, we identified common first-, second-, and third-line chemotherapy regimens for patients with lung cancer and associated utilization and costs of care.
Managed Care and Cancer Outcomes for Medicare Beneficiaries With Disabilities
This study showed better outcomes for disabled Medicare patients with breast cancer but not those with lung cancer when they were enrolled in HMOs.